Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

I also own Eli Lilly, too, so I can handle that pain. Lilly may have the greatest drug franchise of all time with this GLP-1 ...

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed ...

"Ozempic 2.0" has been floating around online, as a trending nickname for the next generation of weight loss drugs that are in the works.

When Marilou Paladin, 42, of Quezon City, began her weight-management journey, her biggest hurdle wasn't portion control. It ...

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have ...